Skip to content

Effect of intravenous acetaminophen in prevention of patent dactus arteriosus in preterm infants

Clinical trial of the effect of intravenous acetaminophen in patent ductus arteriosus prophylaxis of preterm infants with gestational age less than 32 weeks

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20111011007763N2
Enrollment
40
Registered
2018-03-03
Start date
2017-03-20
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent ductus arteriosus. Patent ductus arteriosus

Interventions

Intervention 1: In the intervention group, an intravenous acetaminophen made by Iran Exir Company at a dose of 10 mg/kg is injected each 12 hours. Intervention 2: In the control group, for two days, i

Sponsors

Vice chancellor for research, Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 3 Days

Inclusion criteria

Inclusion criteria: Preterm infants with gestational age <32 weeks

Exclusion criteria

Exclusion criteria: Lethal anomalies Congenital heart diseases Existing patent ductus arteriosus

Design outcomes

Primary

MeasureTime frame
Opening of patent ductus arteriosus. Timepoint: 1 to 3 days after birth. Method of measurement: Echocardiography.

Secondary

MeasureTime frame
Intraventricular hemorrhage. Timepoint: 1 to 3 days after birth. Method of measurement: Brain sonography.;Gastrointestinal bleeding. Timepoint: 1 week. Method of measurement: Clinical examination.;Necrotizing enterocolitis. Timepoint: 1 week. Method of measurement: Clinical examination and stool exam.;Oliguria. Timepoint: 1 week. Method of measurement: Measurement of urine volume.;Pulmonary hemorrhage. Timepoint: 1 week. Method of measurement: Clinical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasim Meh

Mazandaran University of Medical Sciences

nasimmeh62@yahoo.com+98 11 3334 2334

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026